|
🐜
|
Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study
14 auth.
Richard S. Finkel,
C. Chiriboga,
J. Vajsar,
J. Day,
J. Montes,
D. D. De Vivo,
M. Yamashita,
F. Rigo,
G. Hung,
E. Schneider,
...
Daniel A. Norris,
S. Xia,
C. F. Bennett,
K. Bishop
|
9 |
2016 |
9
🐜
|
|
🐜
|
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials
14 auth.
N. Viney,
J. C. V. Capelleveen,
R. Geary,
S. Xia,
J. Tami,
R. Yu,
S. Marcovina,
S. Hughes,
M. Graham,
R. Crooke,
...
S. Crooke,
J. Witztum,
E. Stroes,
S. Tsimikas
|
9 |
2016 |
9
🐜
|
|
🐜
|
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease.
15 auth.
S. Tsimikas,
E. Karwatowska-Prokopczuk,
I. Gouni-Berthold,
J. Tardif,
S. Baum,
E. Steinhagen-Thiessen,
M. Shapiro,
E. Stroes,
P. Moriarty,
B. Nordestgaard,
...
S. Xia,
J. Guerriero,
N. Viney,
L. O’Dea,
J. Witztum
|
9 |
2020 |
9
🐜
|
|
🐜
|
Nusinersen in later-onset spinal muscular atrophy
17 auth.
B. Darras,
C. Chiriboga,
S. Iannaccone,
K. Swoboda,
J. Montes,
L. Mignon,
S. Xia,
C. Bennett,
K. Bishop,
J. Shefner,
...
Allison M. Green,
P. Sun,
I. Bhan,
S. Gheuens,
E. Schneider,
W. Farwell,
D. D. De Vivo
|
7 |
2019 |
7
🐜
|
|
🐜
|
Intrathecal Injections in Children With Spinal Muscular Atrophy
7 auth.
M. Haché,
K. Swoboda,
N. Sethna,
A. Farrow-Gillespie,
A. Khandji,
S. Xia,
...
K. Bishop
|
7 |
2016 |
7
🐜
|
|
🐜
|
N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels
8 auth.
V. Alexander,
S. Xia,
E. Hurh,
S. Hughes,
L. O’Dea,
R. Geary,
...
J. Witztum,
S. Tsimikas
|
7 |
2019 |
7
🐜
|
|
🐜
|
Integrated Safety Assessment of 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers
14 auth.
S. Crooke,
B. Baker,
T. Kwoh,
W. Cheng,
Dan J Schulz,
S. Xia,
Nelson Salgado,
H. Bui,
Christopher E. Hart,
S. Burel,
...
H. Younis,
R. Geary,
S. Henry,
S. Bhanot
|
6 |
2016 |
6
🐜
|
|
🐜
|
Integrated Assessment of the Clinical Performance of GalNAc3-Conjugated 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience
8 auth.
S. Crooke,
B. Baker,
S. Xia,
R. Yu,
N. Viney,
Yanfeng Wang,
...
S. Tsimikas,
R. Geary
|
6 |
2019 |
6
🐜
|
|
🐬
|
Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size.
S. Tsimikas,
S. Fazio,
N. Viney,
S. Xia,
J. Witztum,
S. Marcovina
|
6 |
2018 |
6
🐬
|
|
🐜
|
Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
8 auth.
R. Loomba,
Erin S. Morgan,
L. Watts,
S. Xia,
L. A. Hannan,
R. Geary,
...
B. Baker,
S. Bhanot
|
6 |
2020 |
6
🐜
|
|
🐬
|
Relationship between "LDL-C", estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide.
N. Viney,
C. Yeang,
Xiaohong Yang,
S. Xia,
J. Witztum,
S. Tsimikas
|
5 |
2018 |
5
🐬
|
